Business Week has an excellent article on the chances of Exubera being a commercial success.
Not good would be an understatement!
"But in practical terms, we believe Exubera is more likely to become a disappointment for Pfizer (PFE) -- one that finally helps pharmaceutical and biotechnology companies, and especially investors, recognize that there's a major shift afoot in how managed-care payers make their drug-coverage decisions."
"Exubera doesn't offer an acceptable value proposition. The data simply isn't there to support Exubera's anticipated price, up to four times more than injected insulin."
But it's inhaled!
"The news isn't necessarily good for proponents of inhaled therapies. According to the medical literature, non-compliance with asthma inhalers is rampant -- and of great concern. Patients incorrectly dose on 25% to 80% of days, while 50% use the incorrect inhaling technique."
Insiders' view: This product will be a tough sell. That's notwithstanding the safety concerns I have already noted.
1 comment:
% of Exhubera users that continued to use Exhubera after they discovered the cost?
Post a Comment